165 related articles for article (PubMed ID: 25238166)
1. Low expression of miR-449 in gynecologic clear cell carcinoma.
Jang SG; Yoo CW; Park SY; Kang S; Kim HK
Int J Gynecol Cancer; 2014 Nov; 24(9):1558-63. PubMed ID: 25238166
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma.
Fridley BL; Dai J; Raghavan R; Li Q; Winham SJ; Hou X; Weroha SJ; Wang C; Kalli KR; Cunningham JM; Lawrenson K; Gayther SA; Goode EL
Cancer Epidemiol Biomarkers Prev; 2018 Sep; 27(9):1101-1109. PubMed ID: 29967001
[No Abstract] [Full Text] [Related]
5. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
6. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
Canet B; Pons C; Espinosa I; Prat J
Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
[TBL] [Abstract][Full Text] [Related]
7. Differential transcriptional and protein expression of thyroid-stimulating hormone receptor in ovarian carcinomas.
Gyftaki R; Liacos C; Politi E; Liontos M; Saltiki K; Papageorgiou T; Thomakos N; Haidopoulos D; Rodolakis A; Alevizaki M; Bamias A; Dimopoulos A
Int J Gynecol Cancer; 2014 Jun; 24(5):851-6. PubMed ID: 24844218
[TBL] [Abstract][Full Text] [Related]
8. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
9. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
10. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
[TBL] [Abstract][Full Text] [Related]
11. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
12. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
13. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
Kuo KT; Mao TL; Jones S; Veras E; Ayhan A; Wang TL; Glas R; Slamon D; Velculescu VE; Kuman RJ; Shih IeM
Am J Pathol; 2009 May; 174(5):1597-601. PubMed ID: 19349352
[TBL] [Abstract][Full Text] [Related]
14. [Heterogeneity of epithelial ovarian carcinomas and their clinical significance].
Noske A
Praxis (Bern 1994); 2014 Jan; 103(3):155-9. PubMed ID: 24468455
[TBL] [Abstract][Full Text] [Related]
15. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer.
Mutch DG; Prat J
Gynecol Oncol; 2014 Jun; 133(3):401-4. PubMed ID: 24878391
[No Abstract] [Full Text] [Related]
16. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers.
Dong Y; Kaushal A; Brattsand M; Nicklin J; Clements JA
Clin Cancer Res; 2003 May; 9(5):1710-20. PubMed ID: 12738725
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
[TBL] [Abstract][Full Text] [Related]
18. A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
Langhe R; Norris L; Saadeh FA; Blackshields G; Varley R; Harrison A; Gleeson N; Spillane C; Martin C; O'Donnell DM; D'Arcy T; O'Leary J; O'Toole S
Cancer Lett; 2015 Jan; 356(2 Pt B):628-36. PubMed ID: 25451316
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
Agostini A; Brunetti M; Davidson B; Göran Tropé C; Heim S; Panagopoulos I; Micci F
Int J Cancer; 2018 Sep; 143(6):1379-1387. PubMed ID: 29633253
[TBL] [Abstract][Full Text] [Related]
20. [Expression of mesothelin mRNA and protein in ovarian carcinomas].
Bi SN; Dai SZ; Yao Q; Che YC; Wang N
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):288-91. PubMed ID: 18788634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
